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Background: Scales for aiding physicians diagnose gastro-oesophageal reflux disease (GERD) have not been
evaluated in terms of their ability to discriminate between troublesome symptoms (TS) and non-troublesome
symptoms (NTS). Our objective is to evaluate the ability of the Reflux Disease Questionnaire (RDQ) to identify GERD
according to referral of TS, in patients without previous proton pump inhibitor (PPI) treatment and in patients on
PPI treatment.
Methods: Patients consulting physicians because of heartburn or acid regurgitation were recruited at 926
primary-care centres in Spain. They were asked to complete several questionnaires including the RDQ, and to define
which of their symptoms were troublesome. Information on drug treatment was collected by the physician. We
performed a receiver operating characteristic (ROC) curve analysis to ascertain the RDQ's optimum cut-point for
identifying TS.
Results: 4574 patients were included, 1887 without PPI and 2596 on PPI treatment. Among those without PPI
treatment, 1722 reported TS. The area under the curve (AUC) was 0.79 for the RDQ, and the optimum RDQ
cut-point for identifying TS was 3.18 (sensitivity, 63.2%; specificity, 80.2%). A total of 2367 patients on PPI treatment
reported TS, and the optimum RDQ cut-off value was 3.06 (sensitivity, 65.4%; specificity, 71.8%).
Conclusions: An RDQ score higher than 3 shows good sensitivity and specificity for differentiating TS from NTS
among patients without PPI or on PPI treatment. The RDQ is useful in primary care for diagnosis of GERD based on
the Montreal definition.
Keywords: GERD, Heartburn, Questionnaires, Patient-reported outcomesBackground
In Western societies, 30% [1] to 60% [2] of persons suffer
from heartburn or regurgitation, yet not all those who
report these symptoms suffer from gastro-oesophageal
reflux disease (GERD). Indeed, the differentiation between
frequent and occasional symptoms is unsatisfactory from
a practical standpoint, in view of the fact that a consider-
able proportion of patients with occasional symptoms
consult their physician [3] and suffer from a deterioration
in their quality of life [4]. Consequently, for every patient
that seeks advice, it is the physician who has to decide* Correspondence: marta.barcelo@yahoo.es
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stated.whether the symptoms are irrelevant or circumstantial
(and, by extension, not constitutive of disease), or alterna-
tively, whether the patient is really suffering from GERD.
The Montreal Consensus defines GERD as "a condition
which develops when the reflux of stomach contents
causes troublesome symptoms and/or complications"
[5], the conclusion being that, in clinical practice, it is
the patient who defines whether or not the symptoms
are troublesome, without the use of arbitrary cut-points
of frequency and severity. Any given person's percep-
tion of a symptom as troublesome goes beyond its fre-
quency, its severity or even its impact on quality of life
[6], since it implies individual cognitive assessment
which may vary according to the circumstances [7].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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crucial importance to the physician because it is precisely
on this that his attitude to diagnosis and therapy will so
often depend [8,9]- the Montreal Consensus does not
specify how GERD severity is to be assessed in clinical
practice, thus assuming the degree of severity to be that
reported by the patient [10].
Yet, this commitment to patient-centred clinical practice
comes up against the reality of the fact that, as compared
to the opinion held by their patients, physicians tend to
underestimate the impact of gastro-oesophageal reflux
symptoms [11,12]. To try and minimise the discrepan-
cies between patient-based information and physicians'
subjective evaluation, useful instruments have been de-
veloped to collect information directly from the patient
as uniformly as possible and help physicians diagnose
GERD and assess its severity, e.g., the Reflux Disease
Questionnaire (RDQ) [13-15]. This questionnaire was
developed using definitions of GERD based on symptom
frequency and severity, and its ability to correctly iden-
tify GERD was recently validated using 24-hour pH
monitoring as a gold standard [16]. However, GERD is
usually diagnosed without invasive testing, and the neither
of the following aspects is known: the extent to which the
RDQ is useful for differentiating troublesome from non-
troublesome reflux symptoms, a key factor for diagnosing
GERD within the new conceptual framework proposed
by the Montreal Consensus; and, the RDQ's capacity to
distinguish symptom severity.
Hence, the primary objective of this study was to as-
sess the utility of the RDQ in standard clinical practice
for identifying reflux symptoms defined as troublesome
by the patient. As a secondary objective, we proposed to




This was an observational, cross-sectional multicentre
study conducted at primary-care centres nationwide.
The study was formally approved by the Clinical
Research Ethics Committee of the San Carlos Hospital
(Hospital Clínico San Carlos) in Madrid, and informed
consent was obtained from all participants prior to their
inclusion. Data-collection was performed from September
to November 2007.
Study population and inclusion process
The study enrolled consecutive patients attending a
primary-care facility and presenting with typical GERD
symptoms (heartburn and/or acid regurgitation). Any
patient aged 18 years or over who reported heartburn or
acid regurgitation in the three months preceding the
medical visit was defined as eligible, with the followingdeemed ineligible: patients whose reason for medical
consultation was simply to renew their prescription; pa-
tients with severe diseases which, in the researcher's opin-
ion, could significantly affect health-related quality of life;
and patients unable to read/complete the questionnaires
because of mental or physical disability.
Eligible patients completed a screening questionnaire
containing three questions, with a recall period of three
months. The first two questions referred to whether the
patient had suffered heartburn or acid regurgitation.
These questions were drawn from the GastroEsophageal
Reflux Questionnaire [17], adapted and validated for use
in Spanish [18]. The third question in the screening ques-
tionnaire was aimed at classifying symptoms as trouble-
some or non-troublesome, and was worded as follows,
"Would you say that the burning feeling that rises through
your chest or the liquid coming back into your mouth leav-
ing a bitter or sour taste has been a troublesome problem?"
This question was intended to act as a uniform reminder
to patients for the purpose of reporting troublesome/non-
troublesome symptoms and was reworded in Spanish after
a group of clinical gastroenterologists agreed that the
question was both meaningful and recalled what it meant
to recall.
Patients who reported heartburn or acid regurgitation
in the first two questions of the screening questionnaire
were included in the study. To ensure inclusion of a suf-
ficient number of patients with non-troublesome symp-
toms, each researcher included a patient with symptoms
classified as non-troublesome for every 4 who perceived
their symptoms as troublesome.
Data-collection
Data were drawn from two sources: [1] self-administered
questionnaires designed to collect information directly
from patients; and [2] clinical information collected dir-
ectly by the physician (anamnesis and clinical history)
on the basis of a pre-established form.
Instruments (patient-reported outcomes)
Patients completed a number of questionnaires adminis-
tered to obtain information on reflux symptoms (RDQ),
impact of GERD symptoms (GERD impact scale, GIS),
digestive symptoms and severity of reflux symptoms
(Gastrointestinal Symptom Rating Scale, GSRS), and
quality of life (Quality of Life in Reflux and Dyspepsia,
QOLRAD).
The RDQ was developed to be used as a diagnostic tool
and to monitor treatment response over time. The RDQ
evaluates 6 symptoms covering three domains (heartburn,
regurgitation and upper abdominal pain) using a 6-point
Likert scale to assess frequency and severity within the
preceding week. Each answer was rated from 1 to 6, and
the RDQ mean score was then calculated as the mean of
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scores thus ranged from 1 to 6. The RDQ, which has been
psychometrically validated [13] and shown its utility
for diagnosing GERD [16], has also been adapted and
validated in Spanish [14].
While the GIS is a self-administered questionnaire de-
signed to improve patient-doctor communication and fur-
nish information on treatment outcomes, it has not been
formally validated as a tool for monitoring the response of
GERD symptoms and quality of life to proton pump in-
hibitor (PPI) treatment [19]. The questionnaire scores the
frequency of 9 items and uses a 4-point Likert scale, with
a one-week recall period. The GIS score is calculated as
the mean value of all item responses, with the scale being
scored from 1 to 4, such that the higher the value, the
better the patient. It is a management tool [15] and the
psychometric validity of the Spanish translation has
recently been reported [14].
The GSRS was used to describe subjects' symptom
clusters. The GSRS covers 15 gastrointestinal symptoms
and uses a 7-point Likert scale to rate each symptom.
The GSRS contains five dimensions, which respectively
address "Indigestion" (four items), "Diarrhoea" (3 items),
"Constipation" (3 items), "Abdominal pain" (3 items) and
"Reflux" (2 items) in the preceding week. The GSRS is
scored in such a way that the lower the value, the less se-
vere the perceived gastrointestinal symptoms. The Reflux
dimension (heartburn and acid regurgitation) was used to
assess GERD severity, with a score of less than 3 being
deemed mild and a score of 5 or more, severe [20]. Both
the reliability and validity of the Spanish version of the
GSRS have previously been documented [21].
The impact of upper GI symptoms on quality of life was
assessed using the QOLRAD questionnaire. The QOL-
RAD questionnaire comprises 25 items with a recall
period of one week, grouped into the following dimen-
sions: "Emotional distress"; "Sleep dysfunction"; "Vitality";
"Food/drink problems"; and "Physical/social functioning".
Questions are rated on a 7-point Likert scale and the
global score then calculated, such that the lower the
value, the more severe the impact on health-related quality
of life. The QOLRAD has been documented as being a
reliable, valid and responsive instrument in subjects
with heartburn [22].
Clinical data
Clinical data were recorded directly by the physician in
accordance with pre-coded categories. This information
referred to: socio-demographic data (age, sex, occupational
status, marital status, educational level); anthropometric
data (weight in kg, height in cm); alcohol consumption
(none, a minimum of once per week); smoking habit
(never-smoker, ex-smoker, smoker); associated diseases
(diabetes, arterial hypertension, hypercholesterolaemia,anxiety disorder, depression and asthma); consumption
of medical drugs (calcium antagonists, nitrates, benzodiaz-
epines, nonsteroidal anti-inflammatory drugs, aspirin);
and use of GERD drugs, including antacids, H2-blockers
and PPIs (at any dose and under any guideline). In
addition, physicians were asked to classify the severity of
patients' GERD symptoms as mild, moderate or severe, on
the basis of their own judgement.
Statistical analysis
For analysis purposes, the sample was stratified into two
groups, namely, [1] patients off PPI i.e., patients not re-
ceiving treatment with PPIs, and [2] patients on PPI, i.e.,
patients on treatment with PPIs, given that these represent
two potentially different clinical scenarios. All analyses
were performed separately in both groups, using the same
definitions of variables and test statistics.
Continuous variables were expressed as mean ± standard
deviation (interval) and categorical variables as absolute
and relative frequencies. For comparison purposes, the
Student's T-test was used for continuous variables, and
the Chi-squared or Fisher's Exact test for qualitative
variables. Hypothesis tests were deemed statistically sig-
nificant at p < 0.05.
In line with their responses to the three screening
questions, patients were classified into the following two
groups: [1] troublesome symptoms (TS), i.e., patients with
heartburn and/or regurgitation classified as troublesome;
and [2] non-troublesome symptoms (NTS), i.e., those
who classified their heartburn and/or regurgitation as
non-troublesome.
To assess to what extent factors extraneous to the char-
acteristics of the symptoms influenced the classification of
symptoms as TS or NTS, a logistic regression model was
constructed, including the impact of symptoms as evalu-
ated by the GIS, age, sex, body mass index (BMI), alcohol
consumption and smoking, as well as the presence of
comorbidities.
To evaluate the ability to distinguish between trouble-
some and non-troublesome symptoms in the global RDQ
score, as well as the optimal cut-point, the corresponding
receiver operating characteristic (ROC) curves were plot-
ted. Based on these, the optimal cut-point was calculated,
predefined as that which would maximise Younden's index
(S + Sp-1).
ROC curves were also plotted to ascertain cut-points
in the RDQ scale capable of classifying GERD symptoms
as mild, moderate or severe, with the classification of
severity obtained by the GSRS being used as the gold
standard.
The degree of agreement between severity of GERD
symptoms obtained on the basis of the GSRS, RDQ, and
physicians' subjective evaluation of symptom severity was
estimated using Kappa's weighted index.
Table 1 Characteristics of patients off PPI, stratified according to whether symptoms were non-troublesome or
troublesome
Variable Non-troublesome symptoms (N = 246) Troublesome symptoms (N = 1722)
Age* Mean ± SD 50.0 ± 12.3 52.0 ± 12.8
Gender* % females 123 (50%) 739 (42.9%)
Body mass index Mean ± SD 26.3 ± 3.7 26.9 ± 3.7
Alcohol* Any 188 (76.3%) 1233 (71.6%)
Smoking Current 122 (49.9%) 928 (53.9%)
Former 69 (28%) 408 (23.7%)
Concomitant therapy Calcium blockers 12 (4.9%) 129 (7.5%)
Nitrates 3 (1.2%) 17 (1.0%)
NSAIDs 22 (8.9%) 201 (11.7%)
ASA 9 (3.6%) 86 (5.0%)
Benzodiazepines 29 (11.8%) 219 (12.7%)
Comorbidity Diabetes 17 (6.9%) 141 (8.2%)
Hypertension 63 (25.6%) 513 (29.8%)
Hypercholesterolaemia** 36 (14.6%) 410 (23.9%)
Depression 14 (5.7%) 139 (8.1%)
Anxiety disorder 53 (21.5%) 387 (22.5%)
Asthma 9 (3.6%) 77 (4.5%)
Frequency of symptoms+
Heartburn** Never 46 (18.8%) 124 (7.2%)
Sometimes 143 (58.4%) 708 (41.1%)
Often 48 (19.6%) 699 (40.6%)
Daily 8 (3.3%) 191 (11.1%)
Acid regurgitation** Never 65 (26.9%) 123 (7.2%)
Sometimes 139 (57.4%) 739 (43.1%)
Often 34 (14.0%) 661 (38.5%)
Daily 4 (1.7%) 193 (11.2%)
Chest pain** Never 127 (51.8%) 444 (25.8%)
Sometimes 93 (38.0%) 767 (44.5%)
Often 21 (8.6%) 429 (24.9%)
Daily 4 (1.6%) 82 (4.8%)
Epigastric burning/pain** Never 66 (26.8%) 184 (10.7%)
Sometimes 136 (55.3%) 732 (42.5%)
Often 39 (15.9%) 643 (37.3%)
Daily 5 (2.0%) 163 (9.5%)
Hoarseness** Never 157 (64.6%) 582 (33.9%)
Sometimes 68 (28.0%) 749 (43.6%)
Often 15 (6.2%) 315 (18.3%)
Daily 3 (1.2%) 73 (4.2%)
Impact of symptoms+
Sleep disturbance** Never 106 (43.3%) 233 (13.5%)
Sometimes 115 (46.9%) 938 (54.5%)
Often 24 (9.8%) 478 (27.8%)
Daily 0 (0.0%) 72 (4.2%)
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Table 1 Characteristics of patients off PPI, stratified according to whether symptoms were non-troublesome or
troublesome (Continued)
Eating disturbance** Never 104 (42.4%) 276 (16.0%)
Sometimes 116 (47.3%) 890 (51.7%)
Often 23 (9.4%) 476 (27.6%)
Daily 2 (0.8%) 80 (4.6%)
Disturbance of work** Never 164 (66.9%) 620 (36.0%)
Sometimes 59 (24.1%) 774 (45.0%)
Often 20 (8.2%) 279 (16.2%)
Daily 2 (0.8%) 48 (2.8%)
Cont. + According to GERD Impact Scale.
*p < 0.05, **p < 0.001 (troublesome versus non-troublesome symptoms; chi-squared test).
Table 2 Factors associated with suffering from
troublesome symptoms among patients off PPI
Factor Adjusted odds ratio 95% CI P-value
Hypercholesterolaemia 0.03
No
Yes 1.57 (1.05; 2.34)
Acid regurgitation <0.0001
Never
Sometimes 2.24 (1.54; 3.26)
Often 5.35 (3.24; 8.85)
Daily 8.30 (2.71; 25.42)
Epigastric burning/pain 0.003
Never
Sometimes 1.12 (0.76; 1.66)
Often 2.15 (1.29; 3.59)
Daily 4.35 (1.29; 14.73)
Sleep disturbance <0.0001
Never
Sometimes 2.41 (1.73; 3.36)
Often 3.15 (1.84; 5.42)
Daily - (0; 0)
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Assuming that, once the optimal point has been chosen,
both scales have an S ≥ 70% and an Sp ≥ 70%, and that
there would be no differences between patients on and
those not on PPI treatment, then, based on a sample of
5621 patients, the sensitivity and specificity of each test
could be estimated with a maximum admissible error of
δ1 = ±1.35% and δ2 = ±2.60% respectively. Given that the
inclusion of one patient with NTS was requested for
every 4 with TS, 20% of patients could be assumed to
present with non-troublesome GERD symptoms. These
estimates were calculated with a 95% two-sided confi-
dence interval.
On the assumption that 5% of the patients included in
the study would not be valid for analysis, a total of 5918
patients would have to be included.
Results
On the basis of the screening criteria, the study initially
included a total of 5332 eligible patients attending 926
centres distributed nationwide (48 out of 51 provinces):
758 patients were excluded for not fulfilling the inclusion
and exclusion criteria, due to the lack of some item of
basic information (e.g., age). Accordingly, 4574 (85.8%) pa-
tients were available for analysis; of these, 4410 patients
reported heartburn and 4230 acid regurgitation in the
screening questions.
Patients without PPI treatment
Of the 4574 analysable patients, 1968 (43%) were not on
treatment with PPIs; 1722 (85.7%) regarded their reflux
symptoms as troublesome, and 246 (14.3%) regarded
them as non-troublesome. Table 1 shows the differences
between patients who reported their symptoms as TS and
those who reported them as NTS. As against patients who
reported their symptoms as non-troublesome, patients
with troublesome symptoms were slightly older, a smaller
proportion were women, and a higher proportion con-
sumed no alcohol or consumed it only occasionally, with
the sole difference of note being an appreciably higherproportion of persons diagnosed with hypercholesterol-
emia among patients with TS. All symptoms were more
frequent among patients who reported TS. In the logistic
regression analysis, the factors associated with reporting
TS were, diagnosis of hypercholesterolaemia, frequency
of acid regurgitation, epigastric pain/burning (probably
reflecting related dyspepsia) and sleep disturbance due
to the reflux symptoms, with the pertinent Odds Ratios
(95% CI) being shown in Table 2.
Patients without PPI treatment with TS registered a
significantly higher RDQ mean score than did those with
NTS (3.54 ± 0.94 vs. 2.55 ± 0.77; p = <0.0001). Figure 1
depicts the ROC curves of the global RDQ score for
identification of TS. The area under the ROC (AUC)
was 0.79 for the mean RDQ score. The cut-point of the
RDQ mean score = 3.18
Figure 1 ROC curves for identification of troublesome symptoms with the reflux disease questionnaire in patients off proton pump
inhibitor therapy.
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was 3.18, which yielded a sensitivity of 63.2% and a specifi-
city of 80.2% for identifying TS, and positive and negative
predictive values of 96% and 24% respectively.Patients on PPI
2606 (57%) of the 4574 patients included were receiving
treatment with PPIs, and of these, 2367 (90.8%) reported
their symptoms as troublesome. Table 3 shows the clin-
ical characteristics and symptoms of the two groups.
Among the patients who reported their symptoms as TS
versus NTS, there was a slightly lower proportion of
women, a higher proportion of smokers, and a lower pro-
portion who consumed no alcohol or consumed it only
occasionally. Likewise, there were differences in symptom
frequency between the two groups. As shown in Table 4,
factors associated with reporting TS were frequency of
acid regurgitation, epigastric pain/burning (probably
reflecting related dyspepsia), and sleep disturbance due
to reflux symptoms.
Figure 2 depicts the ROC curves of the global RDQ
score for identification of TS in patients on PPI. The
AUC was 0.74 for the global RDQ score. The cut-point
of the mean RDQ score which maximised Younden's
index was 3.06, which yielded a sensitivity of 65.4% and
specificity of 71.8% for identifying TS, and positive and
negative predictive values of 96% and 17% respectively.Statistical power
Since the target sample size was not attained and the
number of unassessable patients was higher than ex-
pected, we calculated the study's statistical power. In the
case of untreated patients, working with a sample of
1968 patients afforded us a maximum admissible errorof δ1 = ±2.28 percentage units for sensitivity (70%) and
δ2 = ±4.4 percentage units for specificity (70%).
In the case of treated patients, working with a sample
of 2606 patients afforded us a maximum admissible
error of 1 = ±1.98% for sensitivity (70%) and δ2 = ±3.82%
for specificity (70%).
Severity cut-points
The sample was analysed jointly to determine these cut-
points, in view of the fact that between patients on PPI
and patients off PPI there were no relevant differences
in predictive factors of TS, nor substantial differences in
the optimal cut-point of the RDQ scale for identifying
TS in both groups of patients.
Of the 4565 patients who had all the requisite data for
being analysed, we classified 1237 (27.1% [25.8%,28.4%])
as mild, 2313 (50.7% [49.2%,52.1%]) as moderate and
1015 (22.2% [21.0%,23.4%]) as severe, on the basis of the
reflux dimension of GSRS.
Figure 3 shows the ROC curves for identification of
mild and severe symptoms obtained for the RDQ. The
cut-points which maximised Younden's index were 2.8
and 3.9, with a sensitivity and specificity of 78.6% and
74.2% respectively for mild symptoms, and 77.3% and
72.1% respectively for severe symptoms.
Simple percentage agreement between the GSRS clas-
sification and physicians' subjective opinions was only
59.5%, with a weighted Kappa index of 0.38 (95% CI:
(0.36, 0.40). Physician-based classification also showed
poor agreement with classifications based on the RDQ
(0.36; 95% CI [0.34; 0.38]).
Classification of disease severity measured with the
GSRS and RDQ corresponded to deterioration in health-
related quality of life as measured by the QOLRAD
(Figure 4).
Table 3 Characteristics of patients on PPI, stratified according to whether symptoms were non-troublesome or
troublesome
Variable Non-troublesome symptoms (N = 239) Troublesome symptoms (N = 2367)
Age* Mean ± SD 56.5 ± 14.5 55.0 ± 13.2
Gender* % females 113 (47.3%) 718 (41.7%)*
Body mass index Mean ± SD 27.2 ± 3.5 27.1 ± 3.8
Alcohol* Any 121 (50.6%) 1045 (60.7%)*
Smoking Current 97 (40.5%) 888 (51.6%)
Former 95 (39.7%) 520 (30.2%)*
Concomitant therapy Calcium blockers 25 (10.5%) 186 (10.8%)
Nitrates 6 (2.5%) 53 (3.1%)
NSAIDs 28 (11.7%) 201 (11.7%)
ASA 13 (5.4%) 96 (5.6%)
Benzodiazepines 44 (18.3%) 367 (21.3%)
Comorbidity Diabetes 26 (10.8%) 157 (9.1%)
HBP 86 (36.0%) 608 (35.3%)
Hypercholesterolemia 60 (25.1%) 442 (25.7%)
Depression 32 (13.4%) 184 (10.7%)
Anxiety disorder 52 (21.8%) 434 (25.2%)
Asthma** 16 (6.7%) 55 (3.2%)
Frequency of symptoms+
Heartburn Never 69 (28.9%) 211 (8.9%)
Sometimes 108 (45.2%) 1036 (43.8%)
Often 53 (22.2%) 854 (36.1%)
Daily 9 (3.8%) 265 (11.2%)
Acid regurgitation Never 72 (30.1%) 212 (9.0%)
Sometimes 120 (50.2%) 1008 (42.9%)
Often 38 (15.9%) 880 (37.5%)
Daily 9 (3.8%) 248 (10.6%)
Chest pain Never 112 (46.9%) 565 (23.9%)
Sometimes 89 (37.2%) 1054 (44.5%)
Often 29 (12.1%) 614 (26.0%)
Daily 9 (3.8%) 133 (5.6%)
Epigastric burning/pain Never 58 (24.3%) 284 (12.0%)
Sometimes 121 (50.6%) 984 (41.6%)
Often 49 (20.5%) 872 (36.8%)
Daily 11 (4.6%) 227 (9.6%)
Hoarseness Never 131 (55.5%) 784 (33.3%)
Sometimes 70 (29.7%) 1003 (42.6%)
Often 24 (10.2%) 473 (20.1%)
Daily 11 (4.7%) 97 (4.1%)
Impact of symptoms+
Sleep disturbance** Never 96 (40.2%) 385 (16.3%)
Sometimes 99 (41.4%) 1213 (51.3%)
Often 39 (16.3%) 666 (28.2%)
Daily 5 (2.1%) 100 (4.2%)
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Table 3 Characteristics of patients on PPI, stratified according to whether symptoms were non-troublesome or
troublesome (Continued)
Eating disturbance** Never 87 (36.4%) 396 (16.8%)
Sometimes 107 (44.8%) 1079 (45.6%)
Often 37 (15.5%) 756 (32.0%)
Daily 8 (3.3%) 133 (5.6%)
Disturbance of work** Never 135 (56.5%) 801 (33.9%)
Sometimes 78 (32.6%) 1062 (44.9%)
Often 21 (8.8%) 440 (18.6%)
Daily 5 (2.1%) 61 (2.6%)
Cont. + According to GERD Impact Scale.
*p < 0.05, **p < 0.001 (troublesome versus non-troublesome symptoms; chi-squared test).
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Our study's principal contribution is that patients' per-
ception of reflux symptoms as "troublesome" depends,
above all, on the characteristics of the symptoms them-
selves, and that the RDQ is a relatively useful instru-
ment for identifying symptoms regarded as troublesome
by the patient. Accordingly, the RDQ would be useful
for differentiating troublesome from non-troublesome
reflux symptoms (the basis of the Montreal Consensus),
thereby adding value to its recently shown ability to make
a symptom-based diagnosis of GERD among patients with
troublesome upper GI symptoms [16].
The Montreal Consensus [5] lays down a disease defin-
ition based on a situation where the symptoms are per-
ceived as troublesome by the patient and the definition's
application to clinical practice is feasible [23]. Its imple-
mentation depends basically on the physician judging theTable 4 Factors associated with suffering from
troublesome symptoms among patients on PPI
Factor Adjusted odds ratio 95% CI P-value
Heartburn 0.00
Never
Sometimes 2.02 (1.39; 2.93)
Often 2.23 (1.4; 3.54)
Daily 3.74 (1.63; 8.61)
Acid regurgitation <0.0001
Never
Sometimes 1.84 (1.27; 2.66)
Often 4.19 (2.56; 6.86)
Daily 4.16 (1.84; 9.39)
Sleeping disturbance 0.03
Never
Sometimes 1.67 (1.18; 2.36)
Often 1.59 (1; 2.54)
Daily 1.25 (0.45; 3.49)impact of the symptoms relayed to him by the patient as
being or not being troublesome. It is reasonable to surmise
that questions about symptom frequency, severity and
impact on the patient would have been incorporated
into most physicians' anamnesis years ago, and yet there
continues to be discordance between physicians' and
patients' respective subjective impressions, with disease
severity being generally underestimated [11,12,24]. The
use of patient-administered questionnaires can thus help
physicians ascertain the patients' symptoms more ob-
jectively and decide whether such symptoms are indeed
troublesome.
The principal aim of this study was to assess the cap-
acity of a simple scale that is widely used in clinical prac-
tice and clinical studies -the RDQ- to discern typically
troublesome symptoms. In our study, the RDQ displayed
good sensitivity and specificity when it came to distin-
guishing troublesome from non-troublesome symptoms.
This is so in the two principal clinical situations provoked
by patients with typical GERD symptoms, namely, the
need to decide whether the symptoms are constitutive of
disease (GERD diagnosis); and the persistence of symp-
toms with treatment (adequate or inadequate response).
The negative predictive values are low because they de-
pend on prevalence, and in this case, the prevalence of
troublesome symptoms is so high that it increases the
amount of false negatives.
Furthermore, the cut-points for identifying troublesome
symptoms in the RDQ are homogeneous across all pa-
tients, with or without PPI treatment. Patients' perception
of TS appears to be fairly uniform and homogeneous over
the disease course, something that simplifies clinical appli-
cation considerably, since the same result is obtained in
two populations of patients under different circumstances.
It seems reasonable to propose that, as GERD is defined
on the basis of the presence of troublesome symptoms, in-
adequate response to treatment should be defined in like
manner.
Moreover, other recent studies have shown that RDQ is
useful for diagnosis of GERD in real-world practice [25].
RDQ mean score = 3.06
Figure 2 ROC curves for identification of troublesome symptoms with the reflux disease questionnaire in patients receiving proton
pump inhibitor therapy.
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as troublesome are not well known, though there are un-
doubtedly subjective elements personal to each patient,
and it has been reported that in the general population
such perception can depend on factors extraneous to the
symptoms themselves [26]. While the aim of our study
was not specifically to study this aspect, our data suggest
that, among patients who consult primary care physicians,
apart from the frequency of typical symptoms, impact on
sleep is a relevant characteristic in such symptoms being
viewed as troublesome. In this regard, recent studies con-
ducted mainly in Western countries have shown a two-
way relationship between GERD and sleep, in cases where
night-time reflux leads to sleep deprivation and sleep
deprivation per se can exacerbate GERD by enhancing
perception of intra-oesophageal stimuli [27-29]. Other fac-
tors of a socio-cultural nature may have an influence: in
our study, we covered all areas country-wide to try and
minimise the potential impact that these factors mightROC Curve -Mild
Figure 3 ROC curves for identifying severity of symptoms with the rehave. We did not conduct a comprehensive study of all
the potential factors that might exert an influence, psy-
chosocial factors in particular. This was not the primary
goal of the study and would have required increasing
the number of questions to be completed by patients,
thereby endangering compliance with the protocol and,
by extension, putting the primary goal at risk. Neverthe-
less, the fact that depression and anxiety disorder diag-
nosed by the physician may not represent a related
factor, suggests that psychosocial factors play a second-
ary role in the primary care setting. It would seem that
neither other comorbidities nor the use of drugs play a
relevant role, though it has to be said that patients with
severe diseases which might potentially have had a sub-
stantial impact on health-related quality of life were ex-
cluded. It should be noted that hypercholesterolemia
was associated with reporting TS. Although there is no
evident explanation, this does not appear to be a ran-





* p<0.001 compared to mild
Figure 4 Quality of life (Quality of Life in Reflux and Dyspepsia
[QOLRAD] mean score) according to the classification of GERD
severity obtained with the Gastrointestinal Symptom Rating
Scale (GSRS), and the Reflux Disease Questionnaire (RDQ);
*p < 0.001 severe/moderate versus mild.
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http://www.biomedcentral.com/1471-230X/14/17both groups. The fact that it was not associated with TS
among patients on treatment suggests that, in reality,
hypercholesterolemia is associated with GERD rather
than with troublesome symptoms. In this respect, this
association has already been reported by Ponce et al.
[30] in this country and was recently observed in a
population-based study by Eslick and Talley [31]. It has
been pointed out that this association could be medi-
ated by obesity but in our study this relationship per-
sisted after adjusting for BMI. At all events, frequency
of symptoms plus their impact on sleep emerge as the
principal factors for determining TS.
There are no universally accepted severity scales for
GERD, and indeed the use of the GSRS was the only
Spanish-language standard available. Obviously, "severity",
like "troublesome", is a subjective measure and difficult
to define, seeing as many factors can be responsible for
it. Nonetheless, the RDQ displayed a great capacity for
discerning these groups when the GSRS was used as the
standard. This tells us two things: first, that having cut-
points enables patients to be stratified, which is undeni-
ably useful in clinical practice and clinical research alike;
and second, that the scales indirectly indicate a relation-
ship with severity and so express severity quantitatively,
which enables changes in severity to be assessed. It will be
for future studies to demonstrate this.
Our results are important because they mean that a
therapeutic attitude can be uniformly implemented and
treatment escalations can be modulated, and because they
provide a single cut-point for cases where PPIs are or are
not being taken, which is vital when it comes to defining
therapeutic failure for every individual patient.
Our study has a number of strengths. The first is its
large sample size. The inclusion of over 4,500 patientsallowed us, not only to ensure a sufficient number of per-
sons with NTS, but also to provide statistical power to de-
tect small yet potentially relevant effects. Furthermore, the
study population represents clinical reality, in that persons
with troublesome and non-troublesome symptoms who
consulted physicians were studied, free of any interference
in the form of persons with symptoms not seeking medical
consultation. Secondly, all the instruments used to collect
data were validated, with the exception of the question re-
ferring to TS (which solely seeks to represent the clinical
question homogeneously), and the clinical information
was drawn directly from the data source (the physician).
Although the degree to which a given symptom is trouble-
some can be evaluated numerically, as in the case of a re-
cent population-based study [26], we nevertheless feel that
a yes/no question obliges patients to define themselves,
prior to any other question on the impact of symptoms,
and so conforms to the Montreal philosophy, i.e., that it is
for the patient to define what is and what is not trouble-
some. Thirdly, patients from over 900 health centres were
included, thereby avoiding any single-researcher bias vis-
à-vis the patient profile included. Fourthly, the inclusion
criteria were as lax as possible, so as to enable a truly rep-
resentative sample of patients with GERD symptoms seek-
ing medical advice to be included. The exclusions were
only those required by protocol, as well as that of patients
with diseases which might have an important impact on
quality of life.
It is also necessary to acknowledge some limitations.
Our study was observational and thus the validity of the
cut-points was not confirmed in other populations. Even
so, it must be stressed that the same cut-points were
reproduced in both subsamples, which indirectly indicates
the validity of these instruments. No sub-analysis was per-
formed to try and identify the questionnaire items which
were most relevant or even whether the combination of
the two questionnaires or of the most relevant items from
both might have had greater efficacy. The standard used
was strictly based on symptoms and specifically on the
simple specification by the patient that he/she had suffered
from heartburn/acid regurgitation and that this was
troublesome. To what extent this is representative of the
diagnosis obtained using invasive physiological tests is un-
certain. Despite the fact that a recent study reported a low
sensitivity for clinical diagnosis based on the Montreal
Consensus in obese patients [32], the use of the RDQ for
symptom-based diagnosis of GERD in the primary-care
setting has been clinically validated [16], and all clinical
guidelines support symptom-based diagnosis of GERD.
Conclusions
In brief, it can be concluded that patients' perception of
reflux symptoms as troublesome depends, above all, on
the characteristics of the symptoms themselves and that
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http://www.biomedcentral.com/1471-230X/14/17the RDQ in a useful instrument for helping the primary
care physician differentiate relevant from irrelevant reflux
symptoms, which is fundamental for diagnosis of GERD
based on the Montreal Consensus.
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